Key result
A 60-minute session of neuromuscular electrical stimulation reduced glucose levels at 2 hours (184 vs 223 mg/dl) in type 2 diabetes, but did not alter glucose variability or endothelial function.
Why the study?
Neuromuscular electrical stimulation can be an alternative to conventional exercising, but its effects in patients with type 2 diabetes needed evaluation.
Does neuromuscular electrical stimulation improve glucose levels, glucose variability, and endothelial function in individuals with type 2 diabetes?
RCT (n=28)
randomized
Does neuromuscular electrical stimulation improve glucose levels, glucose variability, and endothelial function in individuals with type 2 diabetes?
A single 60-minute session of neuromuscular electrical stimulation acutely reduces glucose levels in patients with type 2 diabetes, though it does not affect glucose variability or vascular function.
Answers are grounded in this paper and cite their sources.
Acute NMES lowers glucose in T2D; extends non-exercise glycemic options but leaves variability and endothelial effects open.
Neuromuscular electrical stimulation (NMES) can be an alternative to conventional exercising. This randomized clinical trial evaluated the effect of NMES in type 2 diabetes patients. Twenty-eight individuals with type 2 diabetes were assigned to NMES (n=14) or NMES-placebo (n=14) applied to knee extensor muscles for 60 minutes. Glucose variability, microvascular function and endothelial function were evaluated through continuous glucose monitoring system, near infrared spectroscopy and flow-mediated dilatation, respectively. Glucose levels (mg/dl) decreased 2h (184 ± 11 vs 223 ±15), 3h (179 ± 12 vs 219 ±14) and 4h (177 ± 12 vs 212 ±12) after NMES, in comparison to NMES-placebo. No differences in glucose variability were found: coefficient of variation (%) at 0-6h (11.4±1.3 vs 11.4±1.2), 6-12h (9.8±1.0 vs 11.6±1.6), 12-18h (15.5±2.0 vs 11.4±2.1), 18-24h (12.8±2.3 vs 10.0±1.6); standard deviation (mg/dl) at 0-6h (21.6±2 vs 24.6±3.5), 6-12h (19.5±1.8 vs 20.3±2.8), 12-18h (29.9±3.5 vs 21.3±2.8),18-24h (22.8±4.1 vs 16.6±2.0) and mean amplitude of glycemic excursions (mg/dl) 54.9±25.0 vs 70.3±35.7. Endothelial and microvascular functions did not change. In conclusion, one acute NMES session was strong enough to trigger glucose reduction in individuals with type 2 DM, but it failed to induce any significant change in glucose variability, endothelial and microvascular functions.
No takes yet. Share an insight, caveat, or question.
Macedo et al. (2024) conducted an RCT in type 2 diabetes (n=28). Neuromuscular electrical stimulation vs. NMES-placebo was evaluated on Glucose levels at 2 hours (mg/dl). A 60-minute session of neuromuscular electrical stimulation reduced glucose levels at 2 hours (184 vs 223 mg/dl) in type 2 diabetes, but did not alter glucose variability or endothelial function.
Synapse has enriched 10 related papers. Consider them for comparative context: